Little Rock, AR – NuShores Biosciences LLC has been awarded a $50,000 grant from Medical Technology Enterprise Consortium, a South Carolina Not-For-Profit Corporation. Their MTEC
Commercialization Program provides education, mentoring, networking, and investment support
services to MTEC members like NuShores to increase their potential for successful development
and commercialization readiness of novel dual-market medical technologies. The funding
makes available to NuShores the MTEC network of subject matter experts and service providers
(M-Corps) to provide support for the business, technical, and regulatory challenges associated
with technology development and commercialization. Specifically, this grant will help prepare
eligible MTEC members such as NuShores for success in offering products or services to military
sponsors and civilian markets post FDA clearance.
In late 2020, NuShores received nearly $3M in MTEC funding with Department of Defense
(DOD) sponsorship to develop and demonstrate a “Factory in a Box” production automation of
NuShores’ family of NuCress™ bone filler scaffold product line. This complementary MTEC
commercialization grant effort will focus on three primary activities: modeling and
analysis of the next generation manufacturing process, market and product pricing
research, and integration of the above data into a new financial model and pro forma
financial statements to support future fund raising. During these activities, Dr. Suhr will train
NuShores staff on the analysis methodology and modeling strategies.
Sharon Ballard, NuShores CEO, praised Dr. Suhr’s contributions to the company’s
commercialization efforts: “This grant allows us to continue our modeling, analysis, and
mentoring efforts Dan has supported through every stage of NuShores’ development. We are
fortunate to be able to continue these critical steps.”
“It is great to continue to work with an experienced, creative, communicator like Dan. His
contribution to this project is essential to making our vision of the Factory in a Box a commercial
reality”, states Alex Biris, NuShores’ CTO, inventor and co-founder as well as Director of UA
Little Rock’s Center for Integrative Nanotechnology Sciences. NuShores is the global exclusive
licensee of the technology being advanced with this grant.
The work will be led by NuShores’ CEO Sharon Ballard and the team of Mark Pelo, NuShores
Manufacturing Manager, Sam Monk, Quality Manager, Karrer Alghazali, PhD, Research
Manager, with participation from NuShores’ nationally recognized consultant experts.
About NuShores Biosciences LLC
NuShores’ vision is to improve the quality of life for people globally and to compete successfully
in the bone and tissue regenerative materials industry. Early studies suggest that NuShores’
licensed, patented technology could deliver improved solutions for bone regeneration while cutting healthcare costs, lowering treatment risks, and reducing healing times. Research results
show that NuShores’ NuCress™ scaffold could offer several benefits that to date are not achieved
by currently marketed bone regeneration products, therefore promising to bring better treatment
outcomes to millions of people with severe injuries. NuShores has the exclusive, global license
from University of Arkansas Little Rock to commercialize university-owned patented and patent-
pending bone regeneration technologies.
For more NuShores information, visit https://nushores.com
About MTEC
The Medical Technology Enterprise Consortium (MTEC) is a 501(c)(3) biomedical technology
consortium collaborating under an Other Transaction Agreement (OTA) with the U.S. Army
Medical Research and Development Command (USAMRDC) that serves those who serve our
nation. Over the last decades, our warfighters have suffered devastating trauma. So much injury,
so many lives compromised. We need solutions and we need them now. In partnership with the
Department of Defense and private support, MTEC is working to prevent injuries and accelerate
the development of revolutionary medical solutions that will enhance wound healing and return
the wounded to fully functioning lives. Ultimately, all citizens will benefit from these technologies
and health care solutions.
To learn more about MTEC, visit https://www.mtec-sc.org
They’ve Said About US
-
The NuShores group has assembled a very strong development team under Dr. Biris and the operational depth needed to bring their novel materials to the market. I am very excited to be contributing to NuShores and Alex’ team.
-
The opportunity to serve on the board of NuShores is exciting and thought-provoking. As an active member of the scientific community with a specific interest in orthopedics, the ongoing research is especially relevant and exciting for me. I am delighted to have to opportunity to help such a robust and creative group move their technology and research efforts forward
-
I am delighted to be working with such a wonderful team on lifechanging technologies and applications. It is an honor to be along for the journey.
-
It is a rare opportunity to be able to support the historic scientific discoveries licensed to NuShores from UA Little Rock that will have a significant positive impact on public health and clinical practices. I am blessed to be able to participate with NuShores team in maturing such scientific breakthroughs to commercial success
-
I am pleased to serve on the NuShores’ Advisory Board and look forward to contributing to their venture’s product successes. There is a need for their innovative NuCress™ bone void filler that has potential use in my areas of medical practice. I look forward to working with the NuShores team in accomplishing the scientific, regulatory and development milestones to make such a product available to physicians and their patients
-
I am very excited to work with the team at NuShores in the development of an enabling technology in tissue regeneration. I have worked with the group for some time now and have the greatest respect for their approach to the challenge and the quality of their research. I believe that the rigor behind their work is world class and will be regarded as a new standard of care in repairing bone loss.
-
I am honored to serve on the advisory board for NuShores Biosciences LLC. I look forward to opportunities to contribute to your efforts with my experience and lessons learned in the areas of science – technology planning and commercialization, and to assist in the clinical aspects to make it available to patients as soon as possible.
